Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.
Gupta A. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Use of DNA repair proteins translated from biomarker screening to predict overall survival in patients with esophageal cancer treated with oxaliplatin chemotherapy
Sharma RA. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
Mclornan DP. et al, (2012), British Journal of Haematology, 157, 413 - 425
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.
Psaila B. et al, (2012), Blood, 119, 4066 - 4072
BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Juric D. et al, (2012), CANCER RESEARCH, 72
Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate.
Khan OA. et al, (2012), Br J Cancer, 106
Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
Khan OA. et al, (2012), British Journal of Cancer, 106
A study of symptoms described by ovarian cancer survivors.
Stavraka C. et al, (2012), Gynecol Oncol, 125, 59 - 64
Germline activating JAK2-mutation in a family with hereditary thrombocytosis
Mead A. et al, (2012), BRITISH JOURNAL OF HAEMATOLOGY, 157, 21 - 21
Germline JAK2 mutation in a family with hereditary thrombocytosis.
Mead AJ. et al, (2012), N Engl J Med, 366, 967 - 969
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
Patterson DM. et al, (2012), Clin Cancer Res, 18, 1415 - 1425
Pulmonary nodules in patients with melanoma--assume nothing.
Murphy F. et al, (2012), Ann Oncol, 23, 545 - 546
Tumor refractoriness to anti-VEGF therapy is mediated by myeloid cell recruitment in malignant melanoma
Helfrich I. et al, (2012), EXPERIMENTAL DERMATOLOGY, 21, e45 - e45
The earliest thymic T cell progenitors sustain B cell and myeloid lineage potential.
Luc S. et al, (2012), Nat Immunol, 13, 412 - 419
Megakaryocytes, malignancy and bone marrow vascular niches.
Psaila B. et al, (2012), J Thromb Haemost, 10, 177 - 188
Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
Gillies RS. et al, (2012), Br J Surg, 99, 239 - 245
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
Dean E. et al, (2012), Br J Cancer, 106, 468 - 474
New challenges in endpoints for drug development in advanced melanoma.
Ribas A. et al, (2012), Clin Cancer Res, 18, 336 - 341
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Kirkwood JM. et al, (2012), Clin Cancer Res, 18, 555 - 567
Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer.
Li HK. et al, (2012), J Clin Oncol, 30, e19 - e20